Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abbott
Asset purchase of coronary and peripheral business line complete
July 30th, 2003
Abbott (ABT) announced that it has completed the asset purchase of the coronary and peripheral interventional business line of the Jomed group for a cash purchase price of EUR 60 million. Abbott announced plans to acquire Jomed in May. "This is a significant milestone in our efforts to build a global cardiovascular device business," said Robert B. Hance, vice president, vascular devices, hospital, products, Abbott Laboratories. "We look forward to integrating the new products into our portfolio and welcoming our new colleagues to the Abbott Vascular Devices (AVD) family." Jomed's broad line of interventional cardiology and...
Source: Biotech Week (2003-07-30)
|
